Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30


Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.

Flory JH, Mushlin AI.

J Clin Epidemiol. 2015 Feb;68(2):200-10. doi: 10.1016/j.jclinepi.2014.09.001. Epub 2014 Nov 26.


Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 Diabetes Mellitus.

Tran MT, Delate T, Bachmann S.

Pharm Pract (Granada). 2008 Apr;6(2):79-87. Epub 2008 Jun 17.


Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease.

Chang E, Park CY, Park SW.

J Diabetes Investig. 2013 Nov 27;4(6):517-24. doi: 10.1111/jdi.12107. Epub 2013 Jul 1. Review.


Peroxisome proliferator-activated receptor activating hypoglycemic effect of Gardenia jasminoides Ellis aqueous extract and improvement of insulin sensitivity in steroid induced insulin resistant rats.

Chen YI, Cheng YW, Tzeng CY, Lee YC, Chang YN, Lee SC, Tsai CC, Chen JC, Tzen JT, Chang SL.

BMC Complement Altern Med. 2014 Jan 18;14:30. doi: 10.1186/1472-6882-14-30.


In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.

Eldor R, DeFronzo RA, Abdul-Ghani M.

Diabetes Care. 2013 Aug;36 Suppl 2:S162-74. doi: 10.2337/dcS13-2003. Review. No abstract available.


Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.

DeFronzo RA, Eldor R, Abdul-Ghani M.

Diabetes Care. 2013 Aug;36 Suppl 2:S127-38. doi: 10.2337/dcS13-2011. No abstract available.


Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial.

Chawla S, Kaushik N, Singh NP, Ghosh RK, Saxena A.

J Pharmacol Pharmacother. 2013 Jan;4(1):27-32. doi: 10.4103/0976-500X.107656.


Differential sensitivities of the vascular K(ATP) channel to various PPAR activators.

Wang Y, Yu L, Cui N, Jin X, Zhu D, Jiang C.

Biochem Pharmacol. 2013 May 15;85(10):1495-503. doi: 10.1016/j.bcp.2013.02.039. Epub 2013 Mar 13.


Metformin and its clinical use: new insights for an old drug in clinical practice.

Cicero AF, Tartagni E, Ertek S.

Arch Med Sci. 2012 Nov 9;8(5):907-17. doi: 10.5114/aoms.2012.31622. Epub 2012 Nov 7.


Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review.

Desouza CV, Shivaswamy V.

Clin Med Insights Endocrinol Diabetes. 2010;3:43-51. Epub 2010 Aug 3.


Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.

Vinaixa M, Rodriguez MA, Samino S, Díaz M, Beltran A, Mallol R, Bladé C, Ibañez L, Correig X, Yanes O.

PLoS One. 2011;6(12):e29052. doi: 10.1371/journal.pone.0029052. Epub 2011 Dec 16.


Risk management in the treatment of type 2 diabetes with pioglitazone.

Derosa G, Salvadeo SA.

Diabetes Metab Syndr Obes. 2009 Jul 1;2:51-60.


Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V; ECLA Study Group.

Cardiovasc Diabetol. 2011 Feb 11;10:18. doi: 10.1186/1475-2840-10-18.


Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells.

Zhang LH, Kamanna VS, Ganji SH, Xiong XM, Kashyap ML.

J Lipid Res. 2010 Aug;51(8):2211-22. doi: 10.1194/jlr.M004481. Epub 2010 Apr 6.


EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage.

Püntmann I, Schmacke N, Melander A, Lindberg G, Mühlbauer B.

BMC Clin Pharmacol. 2010 Mar 16;10:5. doi: 10.1186/1472-6904-10-5.


Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.

Musholt PB, Schöndorf T, Pfützner A, Hohberg C, Kleine I, Fuchs W, Hehenwarter S, Dikta G, Kerschgens B, Forst T.

J Diabetes Sci Technol. 2009 Nov 1;3(6):1442-50.


Redefining the role of thiazolidinediones in the management of type 2 diabetes.

Barnett AH.

Vasc Health Risk Manag. 2009;5(1):141-51. Epub 2009 Apr 8. Review.

Items per page

Supplemental Content

Write to the Help Desk